PetVivo (NASDAQ:PETV) Shares Up 3.4%

PetVivo Holdings, Inc. (NASDAQ:PETV) shot up 3.4% during mid-day trading on Wednesday . The company traded as high as $0.76 and last traded at $0.74. 1,469 shares changed hands during trading, a decline of 97% from the average session volume of 51,394 shares. The stock had previously closed at $0.72.

PetVivo Price Performance

The firm’s 50 day moving average is $0.91 and its 200 day moving average is $1.04. The firm has a market cap of $12.49 million, a P/E ratio of -0.87 and a beta of 2.15. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.90 and a quick ratio of 0.62.

PetVivo (NASDAQ:PETV) last posted its quarterly earnings results on Monday, February 12th. The company reported ($0.12) earnings per share for the quarter. PetVivo had a negative return on equity of 1,319.59% and a negative net margin of 1,016.64%. The company had revenue of $0.60 million during the quarter.

Insider Transactions at PetVivo

In related news, CEO John Lai purchased 150,000 shares of the stock in a transaction dated Monday, April 15th. The stock was purchased at an average price of $0.60 per share, with a total value of $90,000.00. Following the transaction, the chief executive officer now directly owns 1,288,592 shares in the company, valued at $773,155.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 20.10% of the company’s stock.

Institutional Investors Weigh In On PetVivo

An institutional investor recently bought a new position in PetVivo stock. Warberg Asset Management LLC bought a new stake in shares of PetVivo Holdings, Inc. (NASDAQ:PETV) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 27,693 shares of the company’s stock, valued at approximately $29,000. Warberg Asset Management LLC owned about 0.19% of PetVivo at the end of the most recent quarter. Hedge funds and other institutional investors own 24.55% of the company’s stock.

About PetVivo

PetVivo Holdings, Inc, a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses.